Cloroquine Replacement Drugs
OHSU # 1688
Researchers at Oregon Health & Science University and at the Portland VA Medical Center have discovered and optimized a novel class of compounds that are superior to the standard of care. The antimalarial agents are effective at inhibiting proliferation of multi-drug resistant malarial parasites and selected members of this potent class are over 10 times more effective than chloroquine against malaria in mice, thus, demonstrating proof-of-concept.
Malaria remains one of the deadliest diseases in the world today, as it has been for thousands of years. For each of the one million people killed each year, hundreds of millions more suffer from severe illness. The impact of malaria is particularly devastating in sub-Saharan Africa where its victims are primarily young children and pregnant women. This situation is worsened by the growing emergence of Plasmodium parasites that are resistant to multiple drugs including chloroquine, the least expensive and safest antimalarial ever made. Therefore, there is a need for safe and effective anti-malarial agents.
· Greater than 250 million people worldwide are infected each year resulting in >1 million deaths per year
· 85 - 90% of all deaths from malaria occur in children under 5
Dr. Michael Riscoe is the director of the Experimental Chemotherapy Laboratory and he is a Professor in the Molecular Microbiology and Immunology Department at Oregon Health & Science University. Dr. Riscoe's laboratory focuses on the discovery, optimization and development of antiparasitic drugs, especially drugs for treatment and prevention of malaria.
Patent Status, these comounds are represented by two Technology IDs:
Technology 1325 - Patent Published, PCT/US09/064811
Technology 1688 - Patent Published, PCT/US13/021472
OHSU Technologies 1325 and 1688 are available for exclusive licensing.
Kelly, JX, Smilkstein, MJ, Brun, R, Wittlin, S, Cooper, RA, Lane, KD, Janowsky, A, Johnson, RA, Dodean, RA, Winter, R, Hinrichs, DJ, and Riscoe, MK, 2009, Discovery of a Novel Antimalarial Chemotype: Dual-function Acridone Derivatives, Nature 459(7244):270-3.
- Michael Riscoe, SM.MMBI Administration
- Rolf Winter
- Sovitj Pou
- David Hinrichs
- Jane Kelly
- Yuexin Li
- Aaron Nilsen, SM.MMBI Admin
|Published||United States||US 2018/0009760|
For more information, contact:
Senior Technology Development Manager